A Randomized, Placebo Controlled Clinical Trial to Evaluate the Effects of Simvastatin Treatment on Measurements of Lipidomic Biomarkers in Men With Dyslipidemia.

Trial Profile

A Randomized, Placebo Controlled Clinical Trial to Evaluate the Effects of Simvastatin Treatment on Measurements of Lipidomic Biomarkers in Men With Dyslipidemia.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2013

At a glance

  • Drugs Simvastatin (Primary)
  • Indications Dyslipidaemias
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 17 Feb 2012 Actual patient number changed from 40 to 31 as reported by ClinicalTrials.gov.
    • 09 Sep 2010 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 31 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top